enfortumab vedotin

4 · 20 / page

Ask MedXY AI

Latest news

Tag

DermatologysurvivalAntibody-drug conjugate

Enfortumab Vedotin-Induced Cutaneous Toxicity: A Marker of Improved Survival in Advanced Urothelial Carcinoma

By MedXY|Aug 7, 2026

Enfortumab vedotin (EV) therapy in advanced urothelial carcinoma is frequently associated with cutaneous adverse events (cAEs). These EV-induced skin toxicities correlate independently with improved progression-free and overall survival, ev

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

newsenfortumab vedotin

enfortumab vedotin

Latest news

Enfortumab Vedotin-Induced Cutaneous Toxicity: A Marker of Improved Survival in Advanced Urothelial Carcinoma

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

AUC3 2025: Expert Consensus Roadmap for Renal Cell and Urinary Tract Cancer Care

Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer: Patient-Reported Outcomes from the EV-302 Phase 3 Study